On January 11, 2016, the ReNeuron Group plc (AIM: RENE), a leading UK-based stem cell therapy development company, announced that it has been awarded a £2.1 million (just over $3 million) grant from Innovate UK to further advance the company’s emerging exosome nanomedicine platform (http://www.reneuron.com/products/ctx-derived-exosomes/). The grant, entitled “Stem Cell-Derived Exosomes for Regenerative Medicine,” has been awarded under Innovate UK’s Developing Regenerative Medicine & Cell Therapies” grant scheme and will fund a collaborative program of work to be undertaken by ReNeuron, as lead participant, and its collaborators on the grant, namely, the Cell Therapy Catapult and the Department of Biochemical Engineering at University College London. The grant will fund key pre-clinical development work packages relating to ReNeuron’s exosome nanomedicine platform. These include the development of robust manufacturing systems utilizing scalable bioreactors and purification technologies that will enable the production of ReNeuron’s exosomes at a commercial scale. The work program also includes product characterization and potency assay development, as well as pre-clinical efficacy and toxicity testing of the selected exosome nanomedicine candidate. ReNeuron is exploiting the therapeutic potential of exosomes derived from its proprietary stem cell lines. The company is also exploring the potential of its exosomes as a delivery system for gene therapy treatments. Exosomes are lipid-based nanoparticles secreted from all cells and which are believed to play a key role in the transfer of beneficial proteins and particularly non-coding RNAs from one cell to another.
Login Or Register To Read Full Story